Nerandomilast clinical trials
Also written JASCAYD® and BI 1015550.
How each study uses nerandomilast is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the nerandomilast studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 7 Oct 2025 · JASCAYD · NDA 218764 (FDA, Drugs@FDA)
- European Union
- 15 Jul 2026 · Jascayd · EMEA/H/C/006405 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
36 studies that test it; most in 2024 (7)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2013 | 1 |
| 2017 | 2 |
| 2018 | 3 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 4 |
| 2023 | 6 |
| 2024 | 7 |
| 2025 | 3 |
| 2026 | 7 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 34 · Other 2
Boehringer Ingelheim (33) · University of British Columbia (1) · Gipfel Life Sciences GmbH (1) · Scleroderma Research Foundation, Inc. (1)
Often tested with
Tested in the same studies.
Pirfenidone (2) · Nintedanib (1) · Carbamazepine (1) · Bosentan (1) · BI 101550 (1) · LY-2157299 (1) · Amlitelimab (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 5, 3 in phase 3
Studies that test nerandomilast, phase 3 first.
- Apr 2027A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic DiseasesPhase 3 · Boehringer Ingelheim
- Apr 2027A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With NerandomilastPhase 3 · Boehringer Ingelheim
- Jun 2027This Study Evaluates the Safety, Target Engagement, and Preliminary Efficacy of Galunisertib (TGF-βR1/ALK5 Inhibitor)Combined With Nerandomilast (PDE4 Inhibitor) in GREM2-positive ALS, a Biomarker-defined Subgroup Hypothesized to Reflect Heightened TGF-β/SMAD-driven Astrocytic and Fibrotic SignalingPhase 2/3 · Gipfel Life Sciences GmbH
- Nov 2026Platform Clinical Study for Conquering SclerodermaPhase 2 · Scleroderma Research Foundation, Inc.
- Jun 2027This is a Trial Designed to Evaluate the Combination of Nerandomilast With Mycophenolate Across a Wide Variety of Pulmonary Fibrosis Subtypes, With the Aim of Providing Clinicians With Assurance That This is an Appropriate Therapeutic Combination.Phase 4 · University of British Columbia
Studies
Open first, then newest update. How each study uses nerandomilast is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 36
- A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory MyopathiesNot yet recruitingPhase 3Boehringer IngelheimNCT07789015Written as Nerandomilast
- A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary FibrosisRecruitingPhase 3Boehringer IngelheimNCT07201922Written as Nerandomilast
- FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease ProgressionRecruitingPhase 3Boehringer IngelheimNCT07540988Written as Nerandomilast
- A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease (FIBRONEER-chILD)RecruitingPhase 3Boehringer IngelheimNCT07366034Written as Nerandomilast
- Platform Clinical Study for Conquering SclerodermaRecruitingPhase 2Scleroderma Research Foundation, Inc.NCT06195072Written as BI 1015550 (Nerandomilast)
- This is a Trial Designed to Evaluate the Combination of Nerandomilast With Mycophenolate Across a Wide Variety of Pulmonary Fibrosis Subtypes, With the Aim of Providing Clinicians With Assurance That This is an Appropriate Therapeutic Combination.Not yet recruitingPhase 4University of British ColumbiaNCT07570888Written as Nerandomilast 18 mg - adult formulation
- This Study Evaluates the Safety, Target Engagement, and Preliminary Efficacy of Galunisertib (TGF-βR1/ALK5 Inhibitor)Combined With Nerandomilast (PDE4 Inhibitor) in GREM2-positive ALS, a Biomarker-defined Subgroup Hypothesized to Reflect Heightened TGF-β/SMAD-driven Astrocytic and Fibrotic SignalingNot yet recruitingPhase 2/3Gipfel Life Sciences GmbHNCT07321860Written as Galunisertib + Nerandomilast Combination
- A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic DiseasesActive, not recruitingPhase 3Boehringer IngelheimNCT06806592Written as Nerandomilast
- A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With NerandomilastActive, not recruitingPhase 3Boehringer IngelheimNCT06238622Written as Nerandomilast
- A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the BloodCompletedPhase 2Boehringer IngelheimNCT06241560Written as BI 1015550
- A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)CompletedPhase 3Boehringer IngelheimNCT05321082Written as BI 1015550
- A Study in Healthy People to Compare 2 Different Formulations of Nerandomilast Tablets When Taken With or Without FoodCompletedPhase 1Boehringer IngelheimNCT06624072Written as Nerandomilast 18 mg - adult formulation
- A Study in Healthy People to Compare 2 Different Formulations of BI 1015550 Taken With or Without FoodCompletedPhase 1Boehringer IngelheimNCT05428436Written as Reference (R)
- A Study in Healthy Men to Test Whether BI 1015550 Influences the Amount of Nintedanib and Pirfenidone in the BloodCompletedPhase 1Boehringer IngelheimNCT06070610Written as BI 1015550
- A Study in Healthy People to Compare How 2 Different High Dose Formulations of BI 1015550 Are Taken up in the BodyCompletedPhase 1Boehringer IngelheimNCT06393127Written as Nerandomilast
- A Study in Healthy Men to Test Whether BI 1015550 Influences the Amount of Midazolam in the BloodCompletedPhase 1Boehringer IngelheimNCT05550636Written as BI 1015550
- A Study in Healthy People to Compare How 2 Different Low Dose Formulations of BI 1015550 Are Taken up in the BodyCompletedPhase 1Boehringer IngelheimNCT06408870Written as BI 1015550
- A Study to Test How Different Doses of Nerandomilast (BI 1015550) Are Taken up in the Body of Healthy Japanese MenCompletedPhase 1Boehringer IngelheimNCT06139302Written as Nerandomilast
- A Study in Healthy People to Test How BI 1015550 is Taken up in the Body When Given With or Without FoodCompletedPhase 1Boehringer IngelheimNCT06415045Written as BI 1015550
- This Study is Done in Healthy Japanese Volunteers. It Looks at How Different Doses of BI 1015550 Are Taken up in the Body and How Well They Are Tolerated.CompletedPhase 1Boehringer IngelheimNCT03542344Written as BI 1015550 6 mg
Codes
What other systems call nerandomilast · ClinicalTrials.gg INT002017
- MeSH (NLM) C000727475nerandomilastConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) I5DGT51IB8NERANDOMILASTConfirmed FDA, NLM
- NCI Thesaurus C203229NerandomilastOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000727475 | nerandomilast | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | I5DGT51IB8 | NERANDOMILAST | Confirmed FDA, NLM |
| NCI Thesaurus | C203229 | Nerandomilast | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.